Researchers at the Francis Crick Institute, working with the Amsterdam University Medical Centre, have found that immune cells are held back from fighting lung tumours by another type of cell.

Drugs that block a cancer-causing protein called KRAS-G12C are approved for use in lung cancer but the tumours can develop resistance over time.

In new research published in Science Advances, the researchers used imaging mass cytometry to see the distribution of immune cells around lung tumours in mice with KRAS mutations.

They saw that clusters of T cells were gathered near the tumours, as well as dendritic cells. When the mice were given a KRAS inhibitor drug, these cell communities grew in size and were able to enter the tumour.

However, they still couldn’t launch an immune response against the cancer cells. Using computational analysis of the cell clusters, the researchers found that regulatory T cells (Tregs) were stopping immune cell coordination.

When the researchers blocked the action of Tregs, the mice responded better to the KRAS inhibitor, showing reduced tumour growth and longer survival.

Julian Downward, Principal Group Leader of the Oncogene Biology Laboratory at the Crick, and senior author, said: “Lung cancer is one of the hardest types of cancer to treat, so working out how to harness the immune system to better target tumours is so important. Regulatory T cells are designed to stop the immune system from getting out of control, but it’s clear that they aren’t working as they should be next to cancer cells. Adding drugs that block Tregs to our combination treatments could help to reduce resistance to drugs like KRAS inhibitors.”

To avoid the immune system becoming overactive, the researchers are exploring ways to specifically block Tregs in the tissues surrounding tumours.

Diana Spencer, Senior Digital Content Editor, DDW